Literature DB >> 12915238

Ultra-long antagonism of kappa opioid agonist-induced diuresis by intracisternal nor-binaltorphimine in monkeys.

M C H Ko1, K J Willmont, H Lee, G S Flory, J H Woods.   

Abstract

Kappa opioid receptor (KOR) agonists such as U-50488H and bremazocine are analgesics and diuretics. In monkeys, the selective KOR antagonist, nor-binaltorphimine (nor-BNI), produces a long-lasting antagonism of the antinociceptive effects of U-50488H but not those of bremazocine, suggesting that KOR-mediated antinociception may occur through two distinct KORs. The aim of this study was to characterize the antagonist effect of nor-BNI against the diuretic effects of U-50488H and bremazocine in monkeys. Urine outputs were collected over 3 h subsequent to i.m. administration of KOR agonists. Both U-50488H (0.032-1 mg/kg) and bremazocine (0.00032-0.01 mg/kg) dose-dependently increased urine output and the diuretic effect reached a plateau at higher doses. The maximum effect of either U-50488H or bremazocine was approximately 15 ml/kg/3 h of urine. Pretreatment with intracisternal nor-BNI 0.32 mg significantly blocked both U-50488H (0.18 mg/kg)- and bremazocine (0.0032 mg/kg)-induced diuresis for 20 weeks. However, the same dose of nor-BNI 0.32 mg given subcutaneously was not effective. These results demonstrate that central KOR mediate KOR agonist-induced diuresis in monkeys. More important, this study provides functional evidence for a homogenous population of KOR underlying KOR-mediated diuresis and illustrates a unique pharmacological profile of nor-BNI-induced ultra-long KOR antagonism in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12915238      PMCID: PMC2863110          DOI: 10.1016/s0006-8993(03)02938-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  37 in total

1.  Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.

Authors:  M C Ko; E R Butelman; J R Traynor; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

2.  Opiate receptor binding sites in human brain.

Authors:  A Pfeiffer; A Pasi; P Mehraein; A Herz
Journal:  Brain Res       Date:  1982-09-23       Impact factor: 3.252

3.  Systemic and regional hemodynamic and biological effects of a new kappa-opioid agonist, niravoline, in healthy volunteers.

Authors:  E Bellissant; T Denolle; P Sinnassamy; D G Bichet; J F Giudicelli; F Lecoz; J M Gandon; H Allain
Journal:  J Pharmacol Exp Ther       Date:  1996-07       Impact factor: 4.030

4.  Activation of peripheral kappa opioid receptors inhibits capsaicin-induced thermal nociception in rhesus monkeys.

Authors:  M C Ko; E R Butelman; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1999-04       Impact factor: 4.030

5.  Influence of asimadoline, a new kappa-opioid receptor agonist, on tubular water absorption and vasopressin secretion in man.

Authors:  H J Kramer; W Uhl; B Ladstetter; A Bäcker
Journal:  Br J Clin Pharmacol       Date:  2000-09       Impact factor: 4.335

6.  Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. I. Effects of opioid kappa receptor agonists bremazocine and U-50,488 on secretion of PRL and GH: comparison with morphine.

Authors:  L Krulich; J I Koenig; S Conway; S M McCann; M A Mayfield
Journal:  Neuroendocrinology       Date:  1986       Impact factor: 4.914

7.  Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys.

Authors:  M C Ko; M D Johnson; E R Butelman; K J Willmont; H I Mosberg; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1999-12       Impact factor: 4.030

8.  Mechanism of diuretic action of U-62,066E, a kappa opioid receptor agonist.

Authors:  K Yamada; M Imai; S Yoshida
Journal:  Eur J Pharmacol       Date:  1989-01-31       Impact factor: 4.432

9.  Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys.

Authors:  M C Holden Ko; Heeseung Lee; Michael S Song; Katarzyna Sobczyk-Kojiro; Henry I Mosberg; Shiroh Kishioka; James H Woods; Norah N Naughton
Journal:  J Pharmacol Exp Ther       Date:  2003-04       Impact factor: 4.030

10.  Further study of kappa opioids on increased urination.

Authors:  J D Leander
Journal:  J Pharmacol Exp Ther       Date:  1983-10       Impact factor: 4.030

View more
  19 in total

1.  Effectiveness of analogs of the kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic) to reduce U50,488-induced diuresis and stress-induced cocaine reinstatement in rats.

Authors:  Patrick M Beardsley; Gerald T Pollard; James L Howard; F Ivy Carroll
Journal:  Psychopharmacology (Berl)       Date:  2010-04-07       Impact factor: 4.530

Review 2.  Kappa opioid antagonists: past successes and future prospects.

Authors:  Matthew D Metcalf; Andrew Coop
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

3.  Impact of Pharmacological Manipulation of the κ-Opioid Receptor System on Self-grooming and Anhedonic-like Behaviors in Male Mice.

Authors:  Eduardo R Butelman; Bryan D McElroy; Thomas E Prisinzano; Mary Jeanne Kreek
Journal:  J Pharmacol Exp Ther       Date:  2019-04-11       Impact factor: 4.030

4.  Effects of the kappa opioid receptor antagonist nor-binaltorphimine (nor-BNI) on cocaine versus food choice and extended-access cocaine intake in rhesus monkeys.

Authors:  Blake A Hutsell; Kejun Cheng; Kenner C Rice; Sidney Stevens Negus; Matthew L Banks
Journal:  Addict Biol       Date:  2015-01-08       Impact factor: 4.280

5.  Supraspinal actions of nociceptin/orphanin FQ, morphine and substance P in regulating pain and itch in non-human primates.

Authors:  H Ding; K Hayashida; T Suto; D D Sukhtankar; M Kimura; V Mendenhall; M C Ko
Journal:  Br J Pharmacol       Date:  2015-04-24       Impact factor: 8.739

Review 6.  κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction.

Authors:  Eduardo R Butelman; Vadim Yuferov; Mary Jeanne Kreek
Journal:  Trends Neurosci       Date:  2012-06-16       Impact factor: 13.837

7.  Dual action of epidermal growth factor: extracellular signal-stimulated nuclear-cytoplasmic export and coordinated translation of selected messenger RNA.

Authors:  Nien-Pei Tsai; Ya-Lun Lin; Yao-Chen Tsui; Li-Na Wei
Journal:  J Cell Biol       Date:  2010-02-08       Impact factor: 10.539

8.  Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at κ-opioid receptors in striatal neurons.

Authors:  Cullen L Schmid; John M Streicher; Chad E Groer; Thomas A Munro; Lei Zhou; Laura M Bohn
Journal:  J Biol Chem       Date:  2013-06-17       Impact factor: 5.157

9.  Aqueous humor dynamics in monkeys in response to the kappa opioid agonist bremazocine.

Authors:  Carol A Rasmussen; B'Ann True Gabelt; Paul L Kaufman
Journal:  Trans Am Ophthalmol Soc       Date:  2007

10.  Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates.

Authors:  Mei-Chuan Ko; Stephen M Husbands
Journal:  J Pharmacol Exp Ther       Date:  2008-10-08       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.